The preventive effect of Ninjin'yoeito on sarcopenia among patients with advanced urotherial carcinoma who received systemic chemotherapy (A single-center, single-arm, open-label trial)
Not Applicable
- Conditions
- Advanced urothelial carcinoma
- Registration Number
- JPRN-UMIN000044092
- Lead Sponsor
- Hirosaki University hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients can not take a harbal medicine due to dysphagia and/or tube feeding. 2. Patients who have already took other harbal medicines which have supportive roles for cancer treatment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The evaluation of change in the area of psoas muscle 8 weeks after the study.
- Secondary Outcome Measures
Name Time Method The evaluation of change in frailty, body composition, and serum grelin levels 4 and 8 weeks after the study.